首页> 外文OA文献 >Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen

【2h】

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen

机译：在非恶性疾病患者中使用Alemtuzumab，氟达拉滨和美法仑降低强度的条件进行造血细胞移植的经验显示出良好的结果，并且混合嵌合体的风险取决于基础疾病，干细胞来源和Alemtuzumab方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Marsh Rebecca A.; Rao Marepalli B.; Gefen Aharon; Bellman Denise; Mehta Parinda A.; Khandelwal Pooja; Chandra Sharat; Jodele Sonata; Myers Kasiani C.; Grimley Michael; Dandoy Christopher; El-Bietar Javier; Kumar Ashish R.; Leemhuis Tom; Zhang Kejian; Bleesing Jack J.; Jordan Michael B.; Filipovich Alexandra H.; Davies Stella M.;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine|[sol]|melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine|[sol]|busulfan [J] . A Shimoni, I Hardan, N Shem-Tov, Leukemia . 2007,第10期

机译：同种异体造血干细胞移植前两种基于氟达拉滨的低强度调理方案的比较：氟达拉滨| [sol] |美法仑与急性移植物抗宿主病发病率高，非复发死亡率和复发率低相关氟达拉滨| [sol] |白消安
2. Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease (SCD) [J] . Saraf Santosh, Oh Annie, Mahmud Dolores, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2015,第2Suppla1期

机译：成年镰状细胞病（SCD）患者同种异体造血干细胞移植中的Alemtuzumab /低剂量辐射调节方案
3. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using Fludarabine, Carmustine, Melphalan, and Antithymocyte Globulin: Outcomes depend on disease risk index but not age, Comorbidity score, donor type, or human Leukocyte Antigen mismatch [J] . SlackJ.L., DueckA.C., FaubleV.D., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2013,第8期

机译：使用氟达拉滨，卡莫司汀，美法仑和抗胸腺细胞球蛋白降低成人的毒性条件和同种异体干细胞移植：结果取决于疾病风险指数，但不取决于年龄，合并症评分，供体类型或人白细胞抗原失配
4. Fludarabine Phosphete and Melphalan - An Immunosuppressive Reduced Intensity Conditioning (RIC) Regimen for AUogeneic Stem Cell Transplantation in Patients with a Range of Hematological Malignancies [C] . G. Jackson, C. Richardson, G. Morgan, European Haematology Association . 2002

机译：Fludarabine phospete和Melphalan - 一种免疫抑制性降低的强度调理（RIC）治疗患者血液学恶性肿瘤患者的促孕酮干细胞移植方案
5. Symptoms, Cytokines, and Quality of Life of Patients with Chronic Graft-versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation. [D] . Kelly, Debra Lynch. 2014

机译：异基因造血干细胞移植后慢性移植物抗宿主病患者的症状，细胞因子和生活质量。
6. Experience with Alemtuzumab Fludarabine and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease Stem Cell Source and Alemtuzumab Regimen [O] . Rebecca A. Marsh, Marepalli B. Rao, Aharon Gefen, -1

机译：在非恶性疾病患者中使用Alemtuzumab氟达拉滨和美法仑降低强度的条件进行造血细胞移植的经验显示出良好的结果并且混合嵌合体的风险取决于基础疾病干细胞来源和Alemtuzumab方案
7. A Pilot Study of Reduced Intensity Conditioning (RI) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism in Patients With Symptomatic Sickle Cell Disease (SCD) [O] . Bhatia M., Morris E., Moore V., 2009

机译：先兆研究用白消安（Bu），氟达拉滨（Flu）和Alemtuzumab降低强度调节（RI），然后进行同种异体干细胞移植（AlloSCT）以诱导有症状镰状细胞病（SCD）的患者持续混合供体嵌合。

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen

著录项

引文网络

相似文献

相关主题

期刊订阅